4-(4-氯噻吩-2-基)-5-(4-环己基哌嗪-1-基)噻唑-2-胺, 99.9%

4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-amine

UNC 926 hydrochloride, 99%

UNC 926 hydrochloride

7-氯-2H-1,4-苯并恶嗪-3(4H)-酮, 98%

7-Chloro-2H-1,4-benzoxazin-3(4H)-one

6-羟甲基喹啉, 98%

Quinolin-6-ylmethanol

4-[(1E)-2-(2-氨基-4-羟基-5-甲基苯基)偶氮]-N-2-吡啶基苯磺酰胺, 99%

(E)-4-((2-amino-4-hydroxy-5-methylphenyl)diazenyl)-N-(pyridin-2-yl)benzenesulfonamide

2-氨基噻吩-3-羧酸异丙酯

Isopropyl 2-aminothiophene-3-carboxylate

fmoc-(r)-3-氨基-3-(3-溴苯基)-丙酸, 99%

(R)-3-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-(3-bromophenyl)propanoic acid

Fmoc-Trp-Osu, 99%

Fmoc-Trp-Osu

5β-二氢皮质醇21-乙酸盐

5β-Dihydrocortisol 21-acetate

顺-2-羟甲基-1-甲基-1-环己胺

cis-2-hydroxymethyl-1-methyl-1-cyclohexylamine

15-苯基-3,3-二甲基十五碳二烯酸

15-Phenyl-3,3-dimethyl-pentadecanoic acid

香风草甙, 分析对照品,≥99%

Didymin

甲基丙烯酰氧丙基双封端聚二甲基硅氧烷,

Methacryloxypropyl Terminated Polydimethylsiloxanes

ACT 058362; PALOSURAN,, >99%

Palosuran

Calcium-Sensing Receptor Antagonists I , ≥99.9%

Calcium-Sensing Receptor Antagonists I 

Entospletinib, 99.9%

Entospletinib

gamma-DGG, ≥99%

gamma-DGG

4-氟-3-((5-(1-甲基-1H-吡唑-3-基)吡啶-3-基)甲基)氨基)-N-(3-(三氟甲氧基)苯基)苯甲酰胺, ≥99%

VU6015929

Guacetisal , ≥99.9%

Guacetisal 

INF39, 99.9%

INF39